{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,2,21]],"date-time":"2025-02-21T03:10:47Z","timestamp":1740107447143,"version":"3.37.3"},"reference-count":24,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2024,2,19]],"date-time":"2024-02-19T00:00:00Z","timestamp":1708300800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2024,2,19]],"date-time":"2024-02-19T00:00:00Z","timestamp":1708300800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cancer Chemother Pharmacol"],"published-print":{"date-parts":[[2024,6]]},"DOI":"10.1007\/s00280-024-04648-6","type":"journal-article","created":{"date-parts":[[2024,2,19]],"date-time":"2024-02-19T18:02:00Z","timestamp":1708365720000},"page":"565-573","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Multicenter randomized phase II study on S-1 and oxaliplatin therapy as an adjuvant after hepatectomy for colorectal liver metastases (YCOG1001)"],"prefix":"10.1007","volume":"93","author":[{"given":"Mayumi","family":"Ozawa","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7187-3664","authenticated-orcid":false,"given":"Jun","family":"Watanabe","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Atsushi","family":"Ishibe","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Koki","family":"Goto","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yoshiro","family":"Fujii","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kazuya","family":"Nakagawa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yusuke","family":"Suwa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hirokazu","family":"Suwa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hidenobu","family":"Masui","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mitsutaka","family":"Sugita","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yasuhisa","family":"Mochizuki","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shigeru","family":"Yamagishi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Seiji","family":"Hasegawa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yuki","family":"Homma","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Masashi","family":"Momiyama","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Takafumi","family":"Kumamoto","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ryusei","family":"Matsuyama","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kazuhisa","family":"Takeda","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Masataka","family":"Taguri","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Itaru","family":"Endo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2024,2,19]]},"reference":[{"issue":"6","key":"4648_CR1","doi-asserted-by":"publisher","first-page":"394","DOI":"10.3322\/caac.21492","volume":"68","author":"F Bray","year":"2018","unstructured":"Bray F et al (2018) Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin 68(6):394\u2013424","journal-title":"CA Cancer J Clin"},{"issue":"5","key":"4648_CR2","doi-asserted-by":"publisher","first-page":"2553","DOI":"10.3892\/or.2017.5531","volume":"37","author":"MH AlBandar","year":"2017","unstructured":"AlBandar MH, Kim NK (2017) Current status and future perspectives on treatment of liver metastasis in colorectal cancer (Review). Oncol Rep 37(5):2553\u20132564","journal-title":"Oncol Rep"},{"key":"4648_CR3","doi-asserted-by":"publisher","first-page":"810","DOI":"10.1186\/1471-2407-14-810","volume":"14","author":"C Hackl","year":"2014","unstructured":"Hackl C et al (2014) Treatment of colorectal liver metastases in Germany: a ten-year population-based analysis of 5772 cases of primary colorectal adenocarcinoma. BMC Cancer 14:810","journal-title":"BMC Cancer"},{"issue":"1","key":"4648_CR4","doi-asserted-by":"publisher","first-page":"165","DOI":"10.1016\/S1055-3207(02)00091-1","volume":"12","author":"A Altendorf-Hofmann","year":"2003","unstructured":"Altendorf-Hofmann A, Scheele J (2003) A critical review of the major indicators of prognosis after resection of hepatic metastases from colorectal carcinoma. Surg Oncol Clin N Am 12(1):165\u2013192","journal-title":"Surg Oncol Clin N Am"},{"issue":"Spec Issue","key":"4648_CR5","first-page":"12","volume":"8","author":"B Lintoiu-Ursut","year":"2015","unstructured":"Lintoiu-Ursut B, Tulin A, Constantinoiu S (2015) Recurrence after hepatic resection in colorectal cancer liver metastasis -review article. J Med Life 8(Spec Issue):12\u201314","journal-title":"J Med Life"},{"issue":"9","key":"4648_CR6","doi-asserted-by":"publisher","first-page":"e0162400","DOI":"10.1371\/journal.pone.0162400","volume":"11","author":"K Hasegawa","year":"2016","unstructured":"Hasegawa K et al (2016) Adjuvant oral uracil-tegafur with leucovorin for colorectal cancer liver metastases: a randomized controlled trial. PLoS\u00a0ONE 11(9):e0162400","journal-title":"PLoS\u00a0ONE"},{"issue":"1","key":"4648_CR7","doi-asserted-by":"publisher","first-page":"48","DOI":"10.5582\/ddt.8.48","volume":"8","author":"A Saiura","year":"2014","unstructured":"Saiura A et al (2014) A combination of oral uracil-tegafur plus leucovorin (UFT + LV) is a safe regimen for adjuvant chemotherapy after hepatectomy in patients with colorectal cancer: safety report of the UFT\/LV study. Drug Discov Ther 8(1):48\u201356","journal-title":"Drug Discov Ther"},{"issue":"5","key":"4648_CR8","doi-asserted-by":"publisher","first-page":"678","DOI":"10.1002\/bjs5.50174","volume":"3","author":"MA Allard","year":"2019","unstructured":"Allard MA et al (2019) Multicentre study of perioperative versus adjuvant chemotherapy for resectable colorectal liver metastases. BJS Open 3(5):678\u2013686","journal-title":"BJS Open"},{"issue":"3\u20134","key":"4648_CR9","doi-asserted-by":"publisher","first-page":"175","DOI":"10.1159\/000333440","volume":"81","author":"HR Kim","year":"2011","unstructured":"Kim HR et al (2011) Efficacy of oxaliplatin-based chemotherapy in curatively resected colorectal cancer with liver metastasis. Oncology 81(3\u20134):175\u2013183","journal-title":"Oncology"},{"issue":"1","key":"4648_CR10","doi-asserted-by":"publisher","first-page":"133","DOI":"10.1007\/s00280-015-2780-1","volume":"76","author":"I Nakayama","year":"2015","unstructured":"Nakayama I et al (2015) Safety, tolerability, and efficacy of oxaliplatin-based adjuvant chemotherapy after curative resection of hepatic or extrahepatic metastases of Stage IV colorectal cancer. Cancer Chemother Pharmacol 76(1):133\u2013139","journal-title":"Cancer Chemother Pharmacol"},{"issue":"11","key":"4648_CR11","doi-asserted-by":"publisher","first-page":"1125","DOI":"10.1016\/S1470-2045(12)70363-7","volume":"13","author":"YS Hong","year":"2012","unstructured":"Hong YS et al (2012) S-1 plus oxaliplatin versus capecitabine plus oxaliplatin for first-line treatment of patients with metastatic colorectal cancer: a randomised, non-inferiority phase 3 trial. Lancet Oncol 13(11):1125\u20131132","journal-title":"Lancet Oncol"},{"issue":"2","key":"4648_CR12","doi-asserted-by":"publisher","first-page":"100077","DOI":"10.1016\/j.esmoop.2021.100077","volume":"6","author":"J Watanabe","year":"2021","unstructured":"Watanabe J et al (2021) S-1 and oxaliplatin versus tegafur-uracil and leucovorin as post-operative adjuvant chemotherapy in patients with high-risk stage III colon cancer: updated 5-year survival of the phase III ACTS-CC 02 trial. ESMO Open 6(2):100077","journal-title":"ESMO Open"},{"issue":"1","key":"4648_CR13","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1016\/j.clcc.2019.10.002","volume":"19","author":"E Sunami","year":"2020","unstructured":"Sunami E et al (2020) S-1 and oxaliplatin versus tegafur-uracil and leucovorin as postoperative adjuvant chemotherapy in patients with high-risk stage III colon cancer (ACTS-CC 02): a randomized, open-label, multicenter, phase III superiority trial. Clin Colorectal Cancer 19(1):22-31.e6","journal-title":"Clin Colorectal Cancer"},{"issue":"2","key":"4648_CR14","doi-asserted-by":"publisher","first-page":"e153","DOI":"10.1016\/j.clcc.2017.10.015","volume":"17","author":"T Kusumoto","year":"2018","unstructured":"Kusumoto T et al (2018) Planned safety analysis of the ACTS-CC 02 trial: a randomized phase III Trial of S-1 with oxaliplatin versus tegafur and uracil with leucovorin as adjuvant chemotherapy for high-risk stage III colon cancer. Clin Colorectal Cancer 17(2):e153\u2013e161","journal-title":"Clin Colorectal Cancer"},{"issue":"6","key":"4648_CR15","doi-asserted-by":"publisher","first-page":"1034","DOI":"10.1038\/sj.bjc.6604271","volume":"98","author":"Y Yamada","year":"2008","unstructured":"Yamada Y et al (2008) Phase I\/II study of oxaliplatin with oral S-1 as first-line therapy for patients with metastatic colorectal cancer. Br J Cancer 98(6):1034\u20131038","journal-title":"Br J Cancer"},{"issue":"5","key":"4648_CR16","doi-asserted-by":"publisher","first-page":"1001","DOI":"10.1093\/annonc\/mdp464","volume":"21","author":"W Koizumi","year":"2010","unstructured":"Koizumi W et al (2010) Phase II study of oxaliplatin plus S-1 as first-line treatment for advanced gastric cancer (G-SOX study). Ann Oncol 21(5):1001\u20131005","journal-title":"Ann Oncol"},{"key":"4648_CR17","first-page":"1","volume":"10","author":"Y Suwa","year":"2023","unstructured":"Suwa Y, Watanabe J, Suwa H, Ozawa M, Momiyama M, Ishibe A, Nagamine K, Yamagishi S, Ota M, Fukushima T, Sekido H, Saigusa Y, Endo I (2023) Exploratory randomized phase II trial for optimizing treatment dosage and duration of adjuvant S-1 plus oxaliplatin in patients with stage III colon cancer: YCOG1402 (SOAP trial). Ann Gastroenterol Surg 10:1\u201310","journal-title":"Ann Gastroenterol Surg"},{"issue":"34","key":"4648_CR18","doi-asserted-by":"publisher","first-page":"3789","DOI":"10.1200\/JCO.21.01032","volume":"39","author":"Y Kanemitsu","year":"2021","unstructured":"Kanemitsu Y et al (2021) Hepatectomy followed by mFOLFOX6 Versus Hepatectomy alone for liver-only metastatic colorectal cancer (JCOG0603): a phase II or III randomized controlled trial. J Clin Oncol 39(34):3789\u20133799","journal-title":"J Clin Oncol"},{"issue":"13","key":"4648_CR19","doi-asserted-by":"publisher","first-page":"1278","DOI":"10.1016\/S1470-2045(13)70490-X","volume":"14","author":"Y Yamada","year":"2013","unstructured":"Yamada Y et al (2013) Leucovorin, fluorouracil, and oxaliplatin plus bevacizumab versus S-1 and oxaliplatin plus bevacizumab in patients with metastatic colorectal cancer (SOFT): an open-label, non-inferiority, randomised phase 3 trial. Lancet Oncol 14(13):1278\u20131286","journal-title":"Lancet Oncol"},{"key":"4648_CR20","doi-asserted-by":"publisher","first-page":"120","DOI":"10.1186\/1471-2407-8-120","volume":"8","author":"B Gruenberger","year":"2008","unstructured":"Gruenberger B et al (2008) Importance of response to neoadjuvant chemotherapy in potentially curable colorectal cancer liver metastases. BMC Cancer 8:120","journal-title":"BMC Cancer"},{"issue":"13","key":"4648_CR21","doi-asserted-by":"publisher","first-page":"4287","DOI":"10.1245\/s10434-012-2438-8","volume":"19","author":"SM Robinson","year":"2012","unstructured":"Robinson SM et al (2012) Chemotherapy-associated liver injury in patients with colorectal liver metastases: a systematic review and meta-analysis. Ann Surg Oncol 19(13):4287\u20134299","journal-title":"Ann Surg Oncol"},{"issue":"2","key":"4648_CR22","doi-asserted-by":"publisher","first-page":"237","DOI":"10.1097\/SLA.0b013e3182356236","volume":"255","author":"K Lehmann","year":"2012","unstructured":"Lehmann K et al (2012) Chemotherapy before liver resection of colorectal metastases: friend or foe? Ann Surg 255(2):237\u2013247","journal-title":"Ann Surg"},{"issue":"6","key":"4648_CR23","doi-asserted-by":"publisher","first-page":"1281","DOI":"10.1007\/s00280-015-2752-5","volume":"75","author":"T Kato","year":"2015","unstructured":"Kato T et al (2015) Phase II multicenter study of adjuvant S-1 for colorectal liver metastasis: survival analysis of N-SOG 01 trial. Cancer Chemother Pharmacol 75(6):1281\u20131288","journal-title":"Cancer Chemother Pharmacol"},{"issue":"12","key":"4648_CR24","doi-asserted-by":"publisher","first-page":"1620","DOI":"10.1016\/S1470-2045(20)30527-1","volume":"21","author":"T Andr\u00e9","year":"2020","unstructured":"Andr\u00e9 T et al (2020) Effect of duration of adjuvant chemotherapy for patients with stage III colon cancer (IDEA collaboration): final results from a prospective, pooled analysis of six randomised, phase 3 trials. Lancet Oncol 21(12):1620\u20131629","journal-title":"Lancet Oncol"}],"container-title":["Cancer Chemotherapy and Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00280-024-04648-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00280-024-04648-6\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00280-024-04648-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,5,27]],"date-time":"2024-05-27T17:02:29Z","timestamp":1716829349000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00280-024-04648-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,2,19]]},"references-count":24,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2024,6]]}},"alternative-id":["4648"],"URL":"https:\/\/doi.org\/10.1007\/s00280-024-04648-6","relation":{},"ISSN":["0344-5704","1432-0843"],"issn-type":[{"type":"print","value":"0344-5704"},{"type":"electronic","value":"1432-0843"}],"subject":[],"published":{"date-parts":[[2024,2,19]]},"assertion":[{"value":"22 October 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 January 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 February 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"We have no conflicts of interest or financial ties to disclose.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}